Isabella Piassi Godói1,2, Livia Lovato Pires Lemos2, Vânia Eloisa de Araújo3, Braúlio Cesar Bonoto1, Brian Godman4,5, Augusto Afonso Guerra Júnior1,2. 1. Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, sala 1023, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil. 2. SUS Collaborating Centre for Technology Assessment & Excellence in Health, sala 1042, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil. 3. Faculdade de Odontologia, Instituto de Ciências Biológicas e da Saúde, Pontifícia Universidade Católica de Minas Gerais, Av. Dom José Gaspar, 500 Coração Eucaristíco, Belo Horizonte, Minas Gerais, CEP 30535-901, Brazil. 4. University of Strathclyde Glasgow, Institute of Pharmacy & Biomedical Sciences, Pharmacoepidemiology, 161 Cathedral Street, Glasgow G4 0RE, UK. 5. Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, SE-141 86, Stockholm, Sweden.
Abstract
INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem. AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. METHOD: Meta-analysis and systematic review. RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.
INTRODUCTION:Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem. AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. METHOD: Meta-analysis and systematic review. RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.
Authors: Yalil T Bracho-Churio; Ruth A Martínez-Vega; Alfonso J Rodriguez-Morales; Ronald G Díaz-Quijano; María L Luna-González; Fredi A Diaz-Quijano Journal: Ann Clin Microbiol Antimicrob Date: 2017-05-15 Impact factor: 3.944
Authors: Isabella P Godói; André S Santos; Edna A Reis; Livia L P Lemos; Cristina M R Brandão; Juliana Alvares; Francisco A Acurcio; Brian Godman; Augusto A Guerra Júnior Journal: Front Pharmacol Date: 2017-02-02 Impact factor: 5.810
Authors: David Weetman; Basile Kamgang; Athanase Badolo; Catherine L Moyes; Freya M Shearer; Mamadou Coulibaly; João Pinto; Louis Lambrechts; Philip J McCall Journal: Int J Environ Res Public Health Date: 2018-01-28 Impact factor: 3.390